Skip to main content
Top
Published in:

03-01-2024 | Tamoxifen

Chemoprevention—Historical Perspectives and Current Trends

Authors: Chelsea Marin, Anna Weiss, Jessica C. Gooch

Published in: Current Breast Cancer Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

To explore the landmark clinical trials which shaped contemporary chemoprevention practice, discuss trends in chemoprevention uptake, and highlight the obstacles faced along the way.

Recent Findings

Poor chemoprevention uptake has been attributed to numerous factors, most notably fear of side effects and lack of physician recommendation. A lower dose of tamoxifen taken for a shorter period has been shown to be an effective alternative and harbors fewer side effects than the standard regimen for chemoprevention.

Summary

Despite new regimens with more favorable side effect profiles and shorter treatment courses, chemoprevention uptake remains low. Education and decision-support interventions have not proven successful in addressing low uptake. In addition to ongoing trials aimed at maintaining the benefits of therapy while reducing adverse effects, a culture change among providers is needed to destigmatize these risk-reducing medications, with focus on referring appropriate women to specialized breast health centers.
Literature
16.
go back to reference Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48(4):812–5.PubMed Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48(4):812–5.PubMed
18.
47.
49.
Metadata
Title
Chemoprevention—Historical Perspectives and Current Trends
Authors
Chelsea Marin
Anna Weiss
Jessica C. Gooch
Publication date
03-01-2024
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 1/2024
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-023-00517-y

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now